Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2012 | 05:26am CET
   By Rumman Ahmed 
 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at rumman.ahmed@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
12/01 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Yield New Information a..
12/01 BRISTOL MYERS SQUIBB : Trademark Application for "NIVDIREC" Filed
12/01 BRISTOL MYERS SQUIBB : Trademark Application for "IMMVIVUR" Filed
12/01 BRISTOL MYERS SQUIBB : European Commission Approves Bristol-Myers Squibb's Opdiv..
12/01 BRISTOL MYERS SQUIBB : Studies Conducted at Bristol-Myers Squibb on Alcohols Rec..
12/01 BRISTOL MYERS SQUIBB : New Findings from Bristol-Myers Squibb Update Understandi..
12/01 BRISTOL MYERS SQUIBB : New Hepatitis C Virus Study Findings Reported from Bristo..
12/01 BRISTOL MYERS SQUIBB : Trademark Application for "AWAKEN" Filed
12/01 QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck ..
11/30 BRISTOL MYERS SQUIBB : to Take Part at the Citi 2016 Global Healthcare Conferenc..
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01:43a December 2016's 10 Worst CCC Stocks At Various Market Caps
12/01 Heat Biologics' lead product candidate flunks mid-stage bladder cancer study;..
12/01 Vantage Point - Going Small To Hit It Big
12/01 3 Ways To Maximize The Returns Of My Dividend Portfolio
11/29 Merck Boosts Dividend 2% And Has Several Key Growth Drivers
Advertisement
Financials ($)
Sales 2016 19 329 M
EBIT 2016 5 338 M
Net income 2016 4 615 M
Debt 2016 160 M
Yield 2016 2,79%
P/E ratio 2016 20,38
P/E ratio 2017 19,71
EV / Sales 2016 4,85x
EV / Sales 2017 4,64x
Capitalization 93 522 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 61,8 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-17.95%93 522
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
More Results